Latest Capital Management News

FMR Resources has secured a conditional joint venture for a major copper-gold project in Chile, appointed a new managing director, and raised $2.2 million, while progressing exploration in Canada’s rare earth elements sector.

Fat Prophets Global Contrarian Fund Ltd announces a special fully franked dividend of AUD 0.05 per share, coupled with a dividend reinvestment plan offering a 2.5% discount. Key dates for investors are set for late August and September 2025.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

WAM Global Limited has updated its special fully franked dividend and clarified the Dividend Reinvestment Plan price for the six months ending December 2024, offering investors a clear view on income and reinvestment options.

King River Resources reports promising assay results from its Kurundi gold project and encouraging soil anomalies at Kuiper, reinforcing its $2 million exploration push in the Tennant Creek region.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Alternative Investment Trust (ASX, AIQ) announces a special unfranked distribution of AUD 0.04647 per unit, representing a full return of capital payable in early August.

Coast Entertainment Holdings reports a robust FY25 with double-digit growth in visitation and revenue, driven by new attractions and strong promotional campaigns. Despite weather disruptions and cautious international recovery, the company starts FY26 on a high note.

Perpetual Limited reported a 2.5% increase in assets under management to A$226.8 billion for Q4 FY25, driven by strong market performance and inflows. The company reaffirmed its expense guidance and continues to pursue the sale of its Wealth Management business.